Entity

Time filter

Source Type


Yang Y.,Fuzhou General Hospital of Nanjing Military Command
BMC emergency medicine | Year: 2013

To explore the diagnostic procedure of acute fatal chest pain in emergency department (ED) in order to decrease the misdiagnosis rate and shorten the definite time to diagnosis. The ultimate aim is to rescue the patients timely and effectively. Three hundreds and two patients (56.9 ± 11.8 Years, 72% men) complained with acute chest pain and chest distress presenting to our ED were recruited. They were divided into two groups according to visiting time (Group I: from October 2010 to March 2011, Group II: from October 2011 to March 2012). The misdiagnosis rate, definite time for diagnosis and medical expense were analyzed. Patients of Group I were diagnosed by initial doctors who made their diagnosis according to personal experience in outpatient service or rescue room in ED. While patients of Group II were all admitted to rescue room and were diagnosed and rescued according to the acute chest pain screening flow-process diagram. Differences inter-group was compared. The misdiagnosis rate of fatal chest pain in Group I and Group II was 6.8% and 0% respectively, and there was statistic difference (P=0.000). The definite time to diagnosis was 65.3 min and 40.1 min in control and Group II respectively, the difference had statistic significance (P=0.000). And the mean cost for treatment was 787.5/124.5 ¥/$ and 905.5/143.2 ¥/$ respectively, and there was statistic difference too (P=0.012). Treating emergency patients with acute chest pain according to the acute chest pain screening flow-process diagram in rescue room will decrease misdiagnosis apparently, and it can also shorten the definite time to correct diagnosis. It has a remarkable positive role in rescuing patients with acute chest pain timely and effectively. Source


Huang D.E.,Fuzhou General Hospital of Nanjing Military Command
Zhongguo zhen jiu = Chinese acupuncture & moxibustion | Year: 2010

OBJECTIVE: To observe the influence of time factors on acupoint sticking therapy for preventing and treating bronchial asthma. METHODS: Seventy-one cases were randomly divided into a dog days group (n= 30), a Sanjiu days group (n=21) and a daily days group (n=20). They were all treated with ginger moxibustion plus acupoint sticking of Chinese medicine at Dazhui (GV 14) and Feishu (BL 13) etc. This treatment was applied once at the beginning of the first dog days, the middle dog days and the last dog days respectively in the dog days group, and once at the beginning of the first nine days, the middle nine days and the last nine days in coldest days of winter respectively in the Sanjiu days group, and once every other 10 days during 30 days except the dog days or the Sanjiu days in the daily days group. Their therapeutic effects and quality of life and changes of serum level of interleukin 13 (IL-13) were observed. RESULTS: The total effective rate of the dog days group was 83.3% (25/30), the Sanjiu days group and the daily days group were 61.9% (13/21) and 65.0% (15/20) respectively, with no significant differences among three groups (all P>0.05). After treatment, there were no significant differences in quality of life and changes of serum level of IL-13 among three groups, but there were significant differences between before and after treatment (P<0.01, P<0.001). CONCLUSION: Acupoint sticking is an effective therapy for bronchial asthma. It can be practiced in the whole year for the result of this study that medicines and acupoints are the leading factors of this therapy and the time factors have no influence on therapeutic effect. Source


Wang W.,Fuzhou General Hospital of Nanjing Military Command
Libyan Journal of Medicine | Year: 2012

Sorafenib is a multikinase inhibitor thought to target vascular endothelial growth factor and its receptor. The European Medicines Agency (EAMA) and Food and Drug Administration (FDA) approved the use of sorafenib in late-stage hepatic cellular cancer (HCC) on October 30, 2007, and November 19, 2007, respectively. It is the only drug approved for use in the systematic treatment of primary HCC, and it offers renewed hope for middle- and late-stage liver cancer patients. Conventional use of sorafenib is 400 mg orally, twice daily, until tumor progression or patient death. The following is a report of a serious episode of skin rash in a liver cancer patient at our hospital subsequent to treatment with sorafenib. © 2012 WenwuWang. Source


Wang L.,Fuzhou General Hospital of Nanjing Military Command
BMC gastroenterology | Year: 2014

BACKGROUND: To evaluate the safety, efficacy and outcomes of fast-track rehabilitation applied to gastric cancer proximal, distal and total gastrectomy.METHODS: Eighty consecutive patients undergoing gastric cancer resection performed by a single surgeon, received perioperative multimodal rehabilitation. Demographic and operative data, gastrointestinal function, postoperative hospital stays, surgical and general complications and mortality were assessed prospectively.RESULTS: Of the 80 patients (mean age 56.3 years), 10 (12.5%) received proximal subtotal gastrectomy (Billroth I), 38 (47.5%) received distal (Billroth II), and 32 (40%) received total gastrectomy (Roux-en-Y). Mean operative time was 104.9 minutes and intraoperative blood loss was 281.9 ml. Time to first flatus was 2.8 ± 0.5 postoperative days. Patients were discharged at a mean of 5.3 ± 2.2 postoperative days; 30-day readmission rate was 3.8%. In-hospital mortality was 0%; general and surgical complications were both 5%.CONCLUSIONS: Fast-track multimodal rehabilitation is feasible and safe in patients undergoing gastric cancer resection and may reduce time to first flatus and postoperative hospital stays. Source


Zhai Y.N.,Fuzhou General Hospital of Nanjing Military Command
Zhonghua zheng xing wai ke za zhi = Zhonghua zhengxing waike zazhi = Chinese journal of plastic surgery | Year: 2013

To evaluate the efficacy and security of propranolol gel in treatment of Infantile hemangiomas. 51 consecutive infants with hemangiomas from October 2010 to September 2011 in Department of General Surgery Fuzhou General Hospital of Nanjing Military Command were treated with propranolol hydrochloride 3% gel. Changes in hemangioma size, texture, color, tumor blood flow peak were recorded. The results were evaluated using Achauer system, responses of IHs to propranolol were considered scale I (poor) in 4 patient (17.24%), scale II (moderate) in 18 patients (24.14%), scale III (good) in 22 patients (44.83%) and scale IV (excellent) in 7 patients (13.79%). The response of superficial hemangiomas was significantly better than other hemangiomas (P < 0.05), and no significant differences in response among different primary sites (P > 0.05). Topical use of propranolol hydrochloride 3% gel is an effective option for superficial hemangiomas. Source

Discover hidden collaborations